Beta-3 adrenergic receptor agonist for adult with overactive bladder

General objective
  • Yo assess the overall effects of treatment with beta-3 adrenergic receptor agonists in adults with OAB by doing a systematic review and meta-analysis of all available RCTs.
Specific objectives
  • To compare the efficacy and safety of beta-3 adrenergic receptor agonists as an intervention for adult patients with OAB through assessing its effect on the symptoms of urgency, incontinence, nocturia and frequency by making the following comparisons:
    • beta-3 adrenergic receptor agonists versus placebo or no treatment;
    • beta-3 adrenergic receptor agonists versus conservative physical treatments (e.g. bladder training, urge suppression, pelvic floor muscle training).
    • beta-3 adrenergic receptor agonists versus anticholinergic/antimuscarinic drugs (e.g. tolterodine, darifenacin, solifenacin, fesoterodine, oxybutynin, propiverine);
    • beta-3 adrenergic receptor agonists versus intravesical Onabotulinumtoxin A injection;
    • beta-3 adrenergic receptor agonists versus electrical stimulation (non-invasive or implanted);
    • one dose regimen of a beta-3 adrenergic receptor agonist versus another;
    • one frequency of administration of a beta-3 adrenergic receptor agonist versus another;
    • one route of administration of a beta-3 adrenergic receptor agonist versus another;
    • one type of beta-3 adrenergic receptor agonist versus another.

This is a protocol.

Share/Save